204840 — GL Pharm Tech Income Statement
0.000.00%
- KR₩82bn
- KR₩86bn
- KR₩26bn
Annual income statement for GL Pharm Tech, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 10,608 | 11,988 | 12,426 | 16,729 | 26,033 |
Cost of Revenue | |||||
Gross Profit | 2,028 | 3,311 | 3,769 | 4,877 | 8,709 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 15,877 | 14,801 | 15,398 | 18,972 | 28,749 |
Operating Profit | -5,269 | -2,813 | -2,973 | -2,244 | -2,716 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -5,558 | -3,467 | -3,842 | -832 | -3,944 |
Provision for Income Taxes | |||||
Net Income After Taxes | -5,515 | -3,356 | -3,734 | -790 | -3,749 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -5,515 | -3,356 | -3,727 | -790 | -3,749 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -5,515 | -3,356 | -3,727 | -790 | -3,749 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -115 | -73.5 | -69.4 | -41.3 | -65.6 |
Dividends per Share |